Prophylactically, subcutaneous immunization with B16-LX/IL-7 significantly inhibited homologous B16-F10 tumor growth compared to vaccination with irradiated B16-F10 cells loaded with LX strain expressing a red fluorescent protein (RFP) (i.e., B16-LX/RFP), highlighting the antitumor role of IL-7 expression. Here, IL7 is linked to neoplasm.